How well belimumab and voclosporin work for treating lupus kidney inflammation
Updated
Abstract
Funding for this summary was contributed by multiple health organizations to the Institute for Clinical and Economic Review (ICER).
- ICER evaluates evidence on the value of health care interventions.
- Annual policy summit is supported by dues from various health care companies.
- Funding sources include AbbVie, Aetna, and Pfizer, among others.
- Certain individuals received funding from ICER for related work.
Simplified
Funding
Competing interests
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from AbbVie, Aetna, America’s Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Pearson is employed by ICER. Through their affiliated institutions, Tice, Mandrik, Thokala, and Fotheringham received funding from ICER for the work described in this summary.
PubMed